2248. Clinical and Microbiological Outcomes Associated with Real-World Use of Ceftolozane/Tazobactam

BACKGROUND: Ceftolozane/tazobactam (C/T) is a novel cephalosporin/β-lactamase inhibitor combination for treating Gram-negative infections, particularly Pseudomonas aeruginosa (PA). C/T has been FDA-approved for complicated intra-abdominal and urinary tract infections and has just completed a trial i...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabrera, Nicolo, Tran, Truc T, Miller, William R, Dinh, An Q, Hanson, Blake, Munita, Jose M, Shelburne, Samuel A, Aitken, Samuel L, Garey, Kevin W, Puzniak, Laura A, Arias, Cesar A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810387/
http://dx.doi.org/10.1093/ofid/ofz360.1926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810387/
http://dx.doi.org/10.1093/ofid/ofz360.1926

Ejemplares similares